MyCane Technologies Co., Ltd.
Basic information
- Head office
- 1-36, Goryo Ohara, Nishi-Kyō, Kyoto City, Kyoto University Kiyoshi Venture Plaza
- Chief executive
- Kazuo Miyazaki
- Capital
- 30,000,000
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- 2016-07-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
| MiCAN Technologies EUROPA GmbH | ||||||||
| Biolabs Heidelberg | ||||||||
| Nissui Pharmaceuticals Co., Ltd. | ||||||||
| RealTech Fund | ||||||||
| 大阪大学VC |
Network
History
Selected for the Ministry of Economy, Trade and Industry's 'Advanced Problem-Solving Venture Support Project'![]()
Accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry![]()
Development of red blood-like cells for research of infectious diseases (Mpv cells, first product) with Kyoto University and Nagasaki University, patent application![]()
Co-developed with Kyoto University and Nagasaki University an erythrocyte-like cell for infectious disease research (first product Mpv cell) and filed a patent![]()
Established our research and development base at Kyoto University Kiyoshi Venture Plaza (SME Incubation, Kyoto City)![]()
Filed a patent for a myeloid cell line for virus research (second product Mylc cell) with Osaka University and Kumamoto University![]()
Patent application for myeloid cells for research of viruses (Mylc cells, second product) with Osaka University and Kumamoto University![]()
Adopted for the Economic Gardening Support Grant supported by KyotoIndustrial Support Organization 21![]()
Signed a joint research agreement with Nissui Pharmaceutical Co., Ltd. regarding culture media for product development![]()
Signed a collaborative research agreement on the development of culture medium with Nissui Pharmaceutical Co., Ltd.![]()
Raised 127 million yen through a third‑party allocation of shares to Osaka University VC and others (Series ASP)![]()
Raised \127,000,000 by allocation of shares to third parties including Osaka University Venture Capital Co., Ltd. (series A)![]()
Selected for AMED's Improved Technology Support in the Virus and Other Infectious Disease Countermeasure Technology Development Project![]()
elected in Support for Improvement Research, Technology Development Project for Measures to Control Viral Infections, by AMED![]()
Adopted into the New Coronavirus Infection Countermeasure Technology Consolidation Project, won the Excellence Award at the 7th Keishin Regional Entrepreneur Award, and adopted into the Reiwa 2 Strategic Core Technology Advancement Support Project![]()
Raised 189 million yen through a third‑party allocation of shares to RealTech Fund and others (Series A2)![]()
Adopted into NEDO's Research & Development Startup Support Project / Business Development Support for Seed‑stage R&D Startups (STS)![]()
Received the Kyoto Small and Medium Enterprise Technology Award 2021 (Reiwa 3) – Outstanding Technology Award![]()
Won the Grand Prize in the Collaboration Category of the 2nd Wisdom‑1 Grand Prix hosted by the Kyoto Chamber of Commerce and Industry![]()
Won the Grand Prix in the Collaboration Category of the 2nd Wisdom-1 Grand Prix sponsored by the Kyoto Chamber of Commerce and Industry.![]()
Adopted for the “Go-Tech Project” (R&D Support Project for Growth-oriented Small and Medium Enterprises)![]()
Commenced provision of the MylcMAT Kit (research use) – a fever‑inducing substance evaluation kit using immortalized myeloid cells (Mylc)![]()
MyrcMAT Kit (for research), a kit for evaluation of thermogenic substances using immortalized myeloid cells (Mylc), is now available for testing.![]()
Raised 200 million yen through a third‑party allocation of shares to RealTech Fund and others (Series B)![]()
Adopted into NEDO's Deep Tech Startup Support Project PCA Phase (Late‑Stage Practical Research & Development)![]()
Selected for NEDO’s Deep Tech Startup Support Project PCA Phase (Practical Application R&D (late stage))![]()
Patent 'Evaluation method for anti-infective drugs, vaccines, etc. using dead monocyte cells and induced cells' registered.![]()
Patent “Evaluation Method for Anti-infective Drugs, Vaccines, etc. Using Monocyte-Derived Immune Cells and Induced Cells” registered![]()
Started shipping paid prototypes of the thermogenic substance alternative test product (MylcMAT) to Europe.![]()
January 2024 MylcMAT, a fever-inducing substance alternative test product, begins shipping paid prototypes to Europe.![]()
Raised ¥100 million through J-KISS-type stock acquisition rights for the 360ip Japan Fund and others![]()
Obtained ISO9001 certification for the design, development, and manufacturing of the thermogenic substance test cell kit.![]()
Design, Development, and Manufacturing of Cell Testing Kits for Fever-Inducing Substances ISO 9001 Certification Achieved![]()
Obtained ISO9001 certification for the design, development, and manufacturing of the thermogenic substance test cell kit.![]()
Raised ¥280 million through a third-party allotment of new shares to Mitani Sangyo and others (Series B2)![]()
Selected for NEDO Deep Tech Startup Support Project PCA Phase (practical application R&D) for developing the MylcEndo product for the LAL market using immortalized monocyte cells.![]()
NEDO Deep Tech Startup Support Program PCA Phase (Practical Application R&D) selected for “Development of MylcEndo Products for the LAL Market Using Immortalized Monocyte Cells”![]()
News
There is no news.
Public records
National Tax Agency basic information7010001177012
- Trade name
- マイキャン・テクノロジーズ株式会社
- Trade name (kana)
- マイキャンテクノロジーズ
- Name in English
- Corporation type
- 301
- Address
- 〒615-8245 京都府京都市西京区御陵大原1-36京大桂ベンチャープラザ
- Postal code
- 6158245
- Prefecture code
- 26
- City code
- 111
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2016-07-25
- Update date
- 2019-04-26
- Change date
- 2019-04-16
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 3944768
METI gBizINFO7010001177012
- Corporate number
- 7010001177012
- Trade name
- マイキャン・テクノロジーズ株式会社
- Trade name (kana)
- マイキャンテクノロジーズ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 京都府京都市西京区御陵大原1-36京大桂ベンチャープラザ
- Postal code
- 6158245
- Prefecture
- 京都府
- Prefecture code
- 26
- City or district
- 京都市西京区
- City code
- 111
- Street address
- 御陵大原1-36京大桂ベンチャープラザ
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 0
- Status
- Representative
- Capital
- Employees
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2019-04-26
- Key information
- 7010001177012